Thalidomide Ameliorates Cisplatin-Induced Nephrotoxicity by Inhibiting Renal Inflammation in an Experimental Model

Inflammation

Volumn 38, Issue 2, 2015, Pages 476-484

  Amirshahrokhi, Keyvan ^a   Khalili, Ali Reza ^a  

^a ARDABIL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cisplatin; cytokines; nephrotoxicity; nitric oxide; thalidomide

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CREATININE; IL10 PROTEIN, MOUSE; IL1B PROTEIN, MOUSE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; NITRIC OXIDE; PEROXIDASE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY INJURY; ANIMAL; ANIMAL MODEL; BLOOD; CHEMICALLY INDUCED; INFLAMMATION; MALE; METABOLISM; MOUSE; NEPHRITIS; RANDOMIZATION; UREA NITROGEN BLOOD LEVEL;

ACUTE KIDNEY INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; CISPLATIN; CREATININE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MALONDIALDEHYDE; MICE; MODELS, ANIMAL; NEPHRITIS; NITRIC OXIDE; PEROXIDASE; RANDOM ALLOCATION; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84933501468     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9953-7     Document Type: Article

References (28)

1. Lebwohl, D., and R. Canetta. 1998. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. European Journal of Cancer 34: 1522–1534.
2. Miller, R.P., R.K. Tadagavadi, G. Ramesh, and W.B. Reeves. 2010. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2: 2490–2518.
3. Yao, X., K. Panichpisal, N. Kurtzman, and K. Nugent. 2007. Cisplatin nephrotoxicity: a review. American Journal of Medical Sciences 334: 115–124.
4. Capizzi, R.L. 1999. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Seminars in Oncology 26: 72–81.
5. Koyner, J.L., R. Sher Ali, and P.T. Murray. 2008. Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury. Nephron Experimental Nephrology 109: e109–e117.
6. dos Santos, N.A., M.A. Carvalho Rodrigues, N.M. Martins, and A.C. dos Santos. 2012. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Archives of Toxicology 86: 1233–1250.
7. Faubel, S., E.C. Lewis, L. Reznikov, D. Ljubanovic, T.S. Hoke, H. Somerset, D.J. Oh, L. Lu, C.L. Klein, C.A. Dinarello, and C.L. Edelstein. 2007. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. Journal of Pharmacology and Experimental Therapeutics 322: 8–15.
8. Deng, J., Y. Kohda, H. Chiao, Y. Wang, X. Hu, S.M. Hewitt, T. Miyaji, P. McLeroy, B. Nibhanupudy, S. Li, and R.A. Star. 2001. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney International 60: 2118–2128.
9. Tadagavadi, R.K., and W.B. Reeves. 2010. Endogenous IL-10 attenuates cisplatin nephrotoxicity: role of dendritic cells. Journal of Immunology 185: 4904–4911.
10. Amirshahrokhi, K., M. Ghazi-khansari, A. Mohammadi-Farani, and G. Karimian. 2010. Effect of captopril on TNF-α and IL-10 in the livers of bile duct ligated rats. Iranian Journal of Immunology 7: 247–251.
11. Ramesh, G., and W.B. Reeves. 2002. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. Journal of Clinical Investigation 110: 835–842.
12. Chirino, Y.I., and J. Pedraza-Chaverri. 2009. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Experimental and Toxicologic Pathology 61: 223–242.
13. Ramesh, G., and W.B. Reeves. 2004. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney International 65: 490–499.
14. Melchert, M., and A. List. 2007. The thalidomide saga. International Journal of Biochemistry & Cell Biology 39: 1489–1499.
15. Mondello, S., E. Mazzon, R. Di Paola, C. Crisafulli, P. Mondello, M. Buemi, C. Aloisi, and S. Cuzzocrea. 2009. Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model. Shock 32: 332–339.
16. Majumder, S., M. Rajaram, A. Muley, H.S. Reddy, K.P. Tamilarasan, G.K. Kolluru, S. Sinha, J.H. Siamwala, R. Gupta, R. Ilavarasan, S. Venkataraman, K.C. Sivakumar, S. Anishetty, P.G. Kumar, and S. Chatterjee. 2009. Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase. British Journal of Pharmacology 158: 1720–1734.
17. Amirshahrokhi, K., and M. Ghazi-Khansari. 2012. Thalidomide attenuates multiple low-dose streptozotocin-induced diabetes in mice by inhibition of proinflammatory cytokines. Cytokine 60: 522–527.
18. Amirshahrokhi, K. 2013. Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in mice. International Immunopharmacology 17: 210–215.
19. El-Naga, R.N. 2014. Pre-treatment with cardamonin protects against cisplatin-induced nephrotoxicity in rats: impact on NOX-1, inflammation and apoptosis. Toxicology and Applied Pharmacology 274: 87–95.
20. Pabla, N., and Z. Dong. 2008. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney International 73: 994–1007.
21. Ueki, M., M. Ueno, J. Morishita, and N. Maekawa. 2013. D-ribose ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice. Tohoku Journal of Experimental Medicine 229: 195–201.
22. Chirino, Y.I., J. Trujillo, D.J. Sánchez-González, C.M. Martínez-Martínez, C. Cruz, N.A. Bobadilla, and J. Pedraza-Chaverri. 2008. Selective iNOS inhibition reduces renal damage induced by cisplatin. Toxicology Letters 176: 48–57.
23. Tabata, C., R. Tabata, Y. Kadokawa, S. Hisamori, M. Takahashi, M. Mishima, T. Nakano, and H. Kubo. 2007. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. Journal of Immunology 179: 708–714.
24. Chirino, Y.I., R. Hernandez-Pando, and J. Pedraza-Chaverri. 2004. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacology 4: 20.
25. Shimazawa, R., H. Sano, A. Tanatani, H. Miyachi, and Y. Hashimoto. 2004. Thalidomide as a nitric oxide synthase inhibitor and its structural development. Chemical & Pharmaceutical Bulletin (Tokyo) 52: 498–499.
26. Taliyan, R., and P.L. Sharma. 2012. Possible mechanism of protective effect of thalidomide in STZ-induced-neuropathic pain behavior in rats. Inflammopharmacology 20: 89–97.
27. Sahu, B.D., M. Kuncha, G.J. Sindhura, and R. Sistla. 2013. Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation and DNA damage. Phytomedicine 20: 453–560.
28. Gulec, M., M. Iraz, H.R. Yilmaz, H. Ozyurt, and I. Temel. 2006. The effects of ginkgo biloba extract on tissue adenosine deaminase, xanthine oxidase, myeloperoxidase, malondialdehyde, and nitric oxide in cisplatin-induced nephrotoxicity. Toxicology and Industrial Health 22: 125–130.